↓ Skip to main content

Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results

Overview of attention for article published in Prostaglandins, Leukotrienes and Essential Fatty Acids, December 2003
Altmetric Badge

About this Attention Score

  • High Attention Score compared to outputs of the same age (80th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

blogs
1 blog

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results
Published in
Prostaglandins, Leukotrienes and Essential Fatty Acids, December 2003
DOI 10.1016/j.plefa.2003.08.020
Pubmed ID
Authors

Malcolm Peet

Abstract

It has been hypothesised that polyunsaturated fatty acids (PUFA) play an important role in the aetiology of schizophrenia and depression. Evidence supporting this hypothesis for schizophrenia includes abnormal brain phospholipid turnover shown by 31P Magnetic Resonance Spectroscopy, increased levels of phospholipase A2, reduced niacin skin flush response, abnormal electroretinogram, and reduced cell membrane levels of n-3 and n-6 PUFA. In depression, there is strong epidemiological evidence that fish consumption reduces risk of becoming depressed and evidence that cell membrane levels of n-3 PUFA are reduced. Four out of five placebo-controlled double- blind trials of eicosapentaenoic acid (EPA) in the treatment of schizophrenia have given positive findings. In depression, two placebo-controlled trials have shown a strong therapeutic effect of ethyl-EPA added to existing medication. The mode of action of EPA is currently not known, but recent evidence suggests that arachidonic acid (AA) if of particular importance in schizophrenia and that clinical improvement in schizophrenic patients using EPA treatment correlates with changes in AA.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Japan 1 1%
Australia 1 1%
Brazil 1 1%
Unknown 65 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 20%
Student > Bachelor 12 17%
Professor 6 9%
Student > Ph. D. Student 6 9%
Other 5 7%
Other 16 23%
Unknown 10 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 14 20%
Medicine and Dentistry 12 17%
Psychology 10 14%
Biochemistry, Genetics and Molecular Biology 5 7%
Neuroscience 4 6%
Other 9 13%
Unknown 15 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2012.
All research outputs
#6,734,849
of 25,374,917 outputs
Outputs from Prostaglandins, Leukotrienes and Essential Fatty Acids
#346
of 1,152 outputs
Outputs of similar age
#27,308
of 142,657 outputs
Outputs of similar age from Prostaglandins, Leukotrienes and Essential Fatty Acids
#2
of 7 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,152 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 142,657 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.